8490

Taiwan Leader BiotechTPEX:8490 Stock Report

Market Cap

NT$415.8m

7D

6.2%

1Y

-31.1%

Updated

22 Sep, 2021

Data

Company Financials
8490 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

8490 Overview

Taiwan Leader Biotech Corp. researches, develops, and supplies herbal medicines, edible fungi, and health supplements in Taiwan, China, Japan, and other Southeast Asian countries.

Share Price & News

How has Taiwan Leader Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8490 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 8490's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

6.2%

8490

-2.0%

TW Personal Products

-0.8%

TW Market


1 Year Return

-31.1%

8490

-15.1%

TW Personal Products

36.1%

TW Market

Return vs Industry: 8490 underperformed the TW Personal Products industry which returned -15.1% over the past year.

Return vs Market: 8490 underperformed the TW Market which returned 36.1% over the past year.


Shareholder returns

8490IndustryMarket
7 Day6.2%-2.0%-0.8%
30 Day10.5%-0.4%5.6%
90 Day-0.2%-4.5%-0.2%
1 Year-28.5%-31.1%-12.7%-15.1%40.1%36.1%
3 Year-69.7%-70.8%-7.1%-15.6%75.1%57.1%
5 Year-68.4%-69.6%14.3%-0.9%122.8%85.5%

Long-Term Price Volatility Vs. Market

How volatile is Taiwan Leader Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Taiwan Leader Biotech Fundamentals Summary

How do Taiwan Leader Biotech's earnings and revenue compare to its market cap?
8490 fundamental statistics
Market CapNT$415.80m
Earnings (TTM)-NT$33.18m
Revenue (TTM)NT$36.52m

11.4x

P/S Ratio

-12.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
8490 income statement (TTM)
RevenueNT$36.52m
Cost of RevenueNT$23.12m
Gross ProfitNT$13.41m
ExpensesNT$46.59m
Earnings-NT$33.18m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.73
Gross Margin36.71%
Net Profit Margin-90.86%
Debt/Equity Ratio28.6%

How did 8490 perform over the long term?

See historical performance and comparison

Valuation

Is Taiwan Leader Biotech undervalued compared to its fair value and its price relative to the market?

1.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8490's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8490's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8490 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.

PE vs Market: 8490 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8490's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8490 is good value based on its PB Ratio (1.6x) compared to the TW Personal Products industry average (2x).


Future Growth

How is Taiwan Leader Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taiwan Leader Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Taiwan Leader Biotech performed over the past 5 years?

12.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8490 is currently unprofitable.

Growing Profit Margin: 8490 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8490 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.4% per year.

Accelerating Growth: Unable to compare 8490's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8490 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).


Return on Equity

High ROE: 8490 has a negative Return on Equity (-12.59%), as it is currently unprofitable.


Financial Health

How is Taiwan Leader Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 8490's short term assets (NT$187.3M) exceed its short term liabilities (NT$24.9M).

Long Term Liabilities: 8490's short term assets (NT$187.3M) exceed its long term liabilities (NT$73.9M).


Debt to Equity History and Analysis

Debt Level: 8490's debt to equity ratio (28.6%) is considered satisfactory.

Reducing Debt: 8490's debt to equity ratio has increased from 14.8% to 28.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8490 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 8490 has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 15.1% each year.


Dividend

What is Taiwan Leader Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8490's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8490's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8490's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8490's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8490's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Chen Xiang

6.75yrs

Tenure

Mr. Chen Qi Xiang has been President of Taiwan Leader Biotech Corp. since December 16, 2014. Mr. Xiang served as Senior Vice President of He Kang Sheng Technology Co., Ltd. Mr. Xiang served as Acting Chief...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

Taiwan Leader Biotech Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Taiwan Leader Biotech Corp.
  • Ticker: 8490
  • Exchange: TPEX
  • Founded: 2006
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$415.800m
  • Shares outstanding: 49.50m
  • Website: https://www.twleaderlife.com

Number of Employees


Location

  • Taiwan Leader Biotech Corp.
  • No. 81, Chengde Road
  • Section 2
  • Taipei
  • 103
  • Taiwan

Listings


Biography

Taiwan Leader Biotech Corp. researches, develops, and supplies herbal medicines, edible fungi, and health supplements in Taiwan, China, Japan, and other Southeast Asian countries. Its products include antr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 08:33
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.